Search
Now showing items 1-10 of 203
-
A Multi-centre, Adaptive, Randomized, Double-Blind, PlaceboControlled Clinical Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients
This is a multi-centre, adaptive, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of investigational therapeutic agents in combination with standard-of care for the treatment ... -
Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression.
(2020-03-06)OBJECTIVES: To explore the epidemiological information, clinical characteristics, therapeutic outcomes and temporal progression of laboratory findings in 2019-coronavirus disease (COVID-19) patients exposed to lopinavir. ... -
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
(2020-03-18)BACKGROUND: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. METHODS: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients ... -
Breakthrough: Chloroquine Phosphate Has Shown Apparent Efficacy in Treatment of COVID-19 Associated Pneumonia in Clinical Studies
(2020-02-29)The coronavirus disease 2019 (COVID-19) virus is spreading rapidly, and scientists are endeavoring to discover drugs for its efficacious treatment in China. Chloroquine phosphate, an old drug for treatment of malaria, is ... -
COVID-1. Informal consultation on the potential role of chloroquine in the clinical management of COVID 19 infection, draft 13 March 2020
(2020-03-13)Currently, there are no therapeutic agents licensed and available for the treatment of COVID 19. On the 27th of January, WHO convened a meeting of experts to examine the available evidence and prioritize promising therapeutic ... -
A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS coronavirus-A Possible Reference for Coronavirus disease-19 Treatment Option
(2020-02-27)In the past few decades, coronaviruses have risen as a global threat to public health. Currently, the outbreak of coronavirus disease-19 (COVID-19) from Wuhan caused a worldwide panic. There are no specific antiviral ... -
Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19)
The SARS-CoV-2 virus emerged in December 2019 and then spread rapidly worldwide, particularly to China, Japan, and South Korea. Scientists are endeavoring to find antivirals specific to the virus. Several drugs such as ... -
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its caused coronavirus disease 2019 (COVID-19) has been reported in China since December 2019. More than 16% of patients developed ... -
Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial
Importance: WHO has made the assessment that coronavirus disease 2019 (COVID-19) can be characterized as a pandemic. But there is no effective antiviral drug for COVID-19 so far. Objective: To compare the efficacy and ... -
Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity Against Novel Coronavirus (SARS-CoV-2)
(2020-03-20)Purpose: Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects [1]. ...